Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +6.80p +0.43% 1,595.20p 1,598.20p 1,598.60p 1,616.00p 1,591.40p 1,593.00p 8,922,996 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 21.6 79,193.09

Glaxosmithkline Share Discussion Threads

Showing 19701 to 19725 of 19725 messages
Chat Pages: 789  788  787  786  785  784  783  782  781  780  779  778  Older
DateSubjectAuthorDiscuss
18/6/2019
15:06
Blown the chance for a sell @£16.15.
abdullla
18/6/2019
13:49
.......surely this time!!
spoole5
18/6/2019
13:22
…. nobody sell! Nobody speak too soon ….. ;0)
tradermichael
18/6/2019
12:02
Or, as the case may be if sold, buy higher! ;-)
sogoesit
17/6/2019
15:47
The GSK presentation from our company visit on the 5th June is available to view in our members area here. Exclusive to full members: hTTps://sharesoc.ning.com/xn/detail/6389471:Comment:53171
sharesoc
14/6/2019
08:59
That gives you the opportunity to sell high and buy low.
abdullla
14/6/2019
08:25
Soon as this stock gets close to £16 it pulls back and we've seen this so many times.
waldo2020
13/6/2019
16:38
"People do not understand where we would be if there was no research" No treatments. Surely they must realise that????? £1bn per drug to take it from phase 1 to 3 , to the retailers shelf, isn't it and barely 2.10 make it all the way through to phase 3,most fail at Phase 1..
crossing_the_rubicon
13/6/2019
16:19
Market did not like the GSK research program so the share price has reversed its gains,people do not understand where we would be if there was no research.
abdullla
13/6/2019
14:19
GSK links up with US university on genome research Drugmaker will fund 20 scientists in rare partnership with University of CaliforniaS GlaxoSmithKline is launching a rare partnership with an American university through which the UK drugmaker will fund more than 20 scientists at a new laboratory focused on human genome research. hTTps://www.ft.com/content/52b9838c-8d34-11e9-a24d-b42f641eca37
crossing_the_rubicon
13/6/2019
09:11
Are we going to crack the 1600p barrier today and if so can we hold it? Usually falls back again from this level but could this time be different?
warranty
12/6/2019
20:54
'GSK to update on potential cancer treatment at European congress' HTTPS://www.sharecast.com/news/news-and-announcements/gsk-to-update-on-potential-cancer-treatment-at-european-congress--6707892.html
philanderer
12/6/2019
19:11
Rubicon, India is also a big offender.
zicopele
12/6/2019
13:15
Consider where the actives of many patent protected drugs are made.
alphorn
12/6/2019
13:03
@Zico Yep, only generics made in Western countries. Wouldn't touch any churned out Asia side(unless it was in Japan), and would definitely avoid China manufactured ones.
crossing_the_rubicon
12/6/2019
11:10
That book has put me off generics, unless they are manufactured in western countries.
zicopele
11/6/2019
15:25
Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
tradermichael
11/6/2019
15:11
@Zico, Someone who knows the generic is as good as the original but 30% of the price I expect!
crossing_the_rubicon
11/6/2019
14:53
Looks like an intersting boook - https://www.nytimes.com/2019/05/13/books/review/bottle-of-lies-katherine-eban.html
zho
11/6/2019
14:47
Just read an extraordinary book about generic drugs....Bottle of Lies. Who would guy a generic?
zicopele
11/6/2019
12:18
Of possible interest to some.... "We May Pick Up GlaxoSmithKline At Cheaper Prices" Summary Shares trading around $40. Divergences beginning to show. The dividend (although not growing) looks safe for now. hTTps://seekingalpha.com/article/4269525-may-pick-glaxosmithkline-cheaper-prices
crossing_the_rubicon
11/6/2019
12:04
Big mistake of Woodford's selling out of GSK. He was reducing Astra Zeneca as well wasnt he? Does he still hold there? hazy memory. Too much "Unquoted illiquid stuff in his portys is his downfall. When the redemptions came, forced to sell decent stuff.
crossing_the_rubicon
11/6/2019
08:15
£1 = $1.27 ….. ;0)
tradermichael
08/6/2019
08:22
Woodford sold out of Glaxo more than 2 years ago: "Neil Woodford, Britain’s most high-profile fund manager, has sold his entire stake in GlaxoSmithKline because of the drugs maker’s refusal to consider a break-up and his doubts about the sustainability of its dividend." https://www.telegraph.co.uk/investing/shares/neil-woodford-sold-glaxo-bought-lloyds/
zho
08/6/2019
07:19
I assume that Woodford's scramble for cash will not impact GSK's price since I think he sold out a large holding in GSK some time ago when he was calling for a break-up. Who knows (since GSK is neither illiquid nor unlisted) he may become a big buyer of GSK again …… ;0) Neil Woodford’s wounded fund management empire has sold or transferred close to £600m of stock since the suspension of its flagship £3.7bn fund on Monday, as the one-time star UK stockpicker scrambles to raise cash. Signs that Mr Woodford is unwinding his long-held stock positions will heighten fears of a fire sale of assets in the funds, which have already weighed on share prices of companies across the portfolio as scrutiny intensifies of his firm’s recent conduct. Mr Woodford, however, hit back at suggestions he was liquidating his portfolio. “This is categorically not a fire sale,” said a Woodford spokesman. “Neil has sold £95m of stocks this week as he continues to reposition the £3.7bn Woodford Equity Income Fund portfolio.” This week’s stock market trades reflect close to £100m of equity sales by Mr Woodford’s funds, which need to raise liquidity to meet a potentially devastating call for cash when they reopen for trading. The remainder mostly reflect the transfer of shares to new managers of funds for St James’s Place, the wealth manager and longstanding backer that this week yanked a separate £3.5bn investment mandate from Mr Woodford’s firm. Philip Warland, an investment industry grandee who advises UK fund boards, said Mr Woodford needed to “create a liquidity pool of at least £1bn”. “When they reopen it will not just be Kent leaving,” he said in reference to the Kent local authority pension scheme that on Monday unsuccessfully sought the return of its £263m invested in the Equity Income Fund, a demand that triggered the fund’s suspension.
tradermichael
Chat Pages: 789  788  787  786  785  784  783  782  781  780  779  778  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190618 18:56:33